Dr Anna Schultze

Research Fellow
Pharmacoepidemiology - GSK Collaboration

Keppel Street
United Kingdom

Anna is a pharmacoepidemiologist who joined the Electronic Health Records Group at LSHTM in 2020. Before joining LSHTM, Anna worked as a senior research associate at the consultancy firm Evidera, where she designed and managed post-authorisation safety and comparative effectiveness studies, primarily using nationwide Scandinavian health registries. She completed a PhD in epidemiology at UCL in 2017, focusing on HIV drug resistance, and also holds an MSc in Epidemiology from LSHTM and a BSc in Human Sciences from UCL. 


Faculty of Epidemiology and Population Health
Department of Non-communicable Disease Epidemiology


Anna is interested in how we can use routinely collected data to study the effectiveness and safety of commonly used medications. Her current research focuses on the use of self-controlled designs for the analyses of clinical trial extension studies; she is also involved in a number of pharmacoepidemiological studies in COVID-19. 

Research Area
Primary care
Electronic health records
Randomised controlled trials

Selected Publications

Incidence and prevalence of venous thromboembolism in Norway 2010-2017.
Ghanima W; Brodin E; Schultze A; Shepherd L; Lambrelli D; Ulvestad M; Ramagopalan S; Halvorsen S
Thrombosis research
Ethnic differences in COVID-19 infection, hospitalisation, and mortality: an OpenSAFELY analysis of 17 million adults in England
Mathur R; Rentsch C; Morton C; Hulme W; Schultze A; MacKenna B; Eggo R; Bhaskaran K; Wong AYS; Williamson E
Hydroxychloroquine for prevention of COVID-19 mortality: a population-based cohort study
Rentsch C; DeVito N; MacKenna B; Morton C; Bhaskaran K; Brown J; Schultze A; Hulme W; Croker R; Walker A
Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study.
Rentsch CT; Kidwai-Khan F; Tate JP; Park LS; King JT; Skanderson M; Hauser RG; Schultze A; Jarvis CI; Holodniy M
PLOS Medicine
Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform.
Schultze A; Walker AJ; MacKenna B; Morton CE; Bhaskaran K; Brown JP; Rentsch CT; Williamson E; Drysdale H; Croker R
The Lancet. Respiratory medicine
Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis
The OpenSAFELY Collaborative; Schultze A; Walker A; MacKenna B; Morton C; Bhaskaran K; Brown J; Rentsch C; Williamson E; Drysdale H
Factors associated with COVID-19-related death using OpenSAFELY.
Williamson EJ; Walker AJ; Bhaskaran K; Bacon S; Bates C; Morton CE; Curtis HJ; Mehrkar A; Evans D; Inglesby P
OpenSAFELY: Do adults prescribed Non-steroidal anti-inflammatory drugs have an increased risk of death from COVID-19?
Wong AYS; MacKenna B; Morton C; Schultze A; Walker A; Bhaskaran K; Brown J; Rentsch C; Williamson E; Drysdale H
See more Publications